	US 12,458,690 B2
	African swine fever virus vaccine
Petrus Theodorus Johannes Willemsen, Amsterdam (NL); and Bernardus Petrus Hubertus Peeters, Lelystad (NL)
Assigned to STICHTING WAGENINGEN RESEARCH, Wageningen (NL)
Appl. No. 17/276,790
Filed by Stichting Wageningen Research, Wageningen (NL)
PCT Filed Sep. 18, 2019, PCT No. PCT/NL2019/050614 § 371(c)(1), (2) Date Mar. 16, 2021, PCT Pub. No. WO2020/060403, PCT Pub. Date Mar. 26, 2020.
Claims priority of application No. 18195280 (EP), filed on Sep. 18, 2018; and application No. 201910239547.X (CN), filed on Mar. 27, 2019.
Prior Publication US 2022/0047694 A1, Feb. 17, 2022
Int. Cl. A61K 39/187 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/187 (2013.01) [C12N 7/00 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/552 (2013.01); A61K 2039/70 (2013.01); C12N 2710/12022 (2013.01); C12N 2710/12023 (2013.01); C12N 2710/12034 (2013.01); C12N 2710/24043 (2013.01); C12N 2710/24143 (2013.01)]

14 Claims

1. A vaccine comprising an effective immunizing amount of a recombinant nucleic acid molecule, comprising an expression cassette encoding a polyepitope comprising T-cell antigens from proteins of African Swine Fever Virus comprising 2-50 nonapeptides as T-cell antigens selected from SEQ ID NOs: 2-14 and 16-21, wherein the T-cell antigens are separated by spacers that contain signals for proteasome cleavage, selected from spacer sequences ARY, NQF, RRW, AQW, and/or SEQ ID NOs: 22-28, and wherein said vaccine further comprises a viral particle comprising B-cell antigens of African Swine Fever Virus, selected from proteins p30, p54, p72, EP402R, A104R and/or B602L of African Swine Fever Virus, wherein the recombinant molecule comprises the nucleotide sequence of SEQ ID NO: 33.